“Higher” Oncotype score & hormonal therapy only?

Options
CPB1167
CPB1167 Member Posts: 24

Hello,

I hope it is ok to ask this question here, I am 50 years old and I found out my Onco score is 27. I had a mastectomy (left breast) and no node involvement. My MO wasn't happy with my score and thought my score would have been lower because My receptor status was so strong. I am trying to weigh out if the risk of the side effects of chemo are worth it. My 10 year risk of recurrence with hormone treatment alone is 18% and with adding chemo it would be around 11%.

Thanks for any help

Comments

  • Meow13
    Meow13 Member Posts: 4,859
    edited September 2018

    What is your cancer grade and mitotic score? I had an oncodx score of 34 and I didn't do chemo against recommendations. I had 2 tumors each 1cm no nodes, grade 1 & 2 er 95% pr 0%. My mitotic scores were 1 on both tumors. I did 4 years on AI drugs.

    I also had left mastectomy.

  • molliefish
    molliefish Member Posts: 723
    edited September 2018

    and what is your recurrence score with rads and hormone tx? I scored 36 oncotype with a grade 3 stage 1 tumour. I weighed everything very carefully and decided on all 3 tx. But would gleefully have bypassed chemo if at all possible.
  • edwards750
    edwards750 Member Posts: 3,761
    edited September 2018

    It’s a tough call but one only you should make because after all it’s your body and your life. That’s not to say you shouldn’t strongly consider the advice of your medical team because they are the experts.

    Then there are the side effects that will probably come with having chemo.
    There are ladies who have had minimal side effects and others who suffered debilitating ones with chemo. There’s no way to know beforehand how it will be for you. What about your QOL?

    I didn’t have chemo because my score was 11. I had IDC, Stage 1b, Grade 1. I had a lumpectomy and radiation - 33 treatments in all. I had a little burning
    and fatigue halfway through my treatments but that’s it. I’m not sure what I would have done if I had been faced with the decision to have chemo or not.

    You of course can roll the dice. Just be sure you don’t second guess yourself or look back and wonder what if..

    Good luck whatever you decide.

    Diane
  • Meow13
    Meow13 Member Posts: 4,859
    edited September 2018

    I think if mine had been grade 3 and larger size I would have thought more about it especially with the oncodx of 34. Also need to understand the risks associated with treatment.

  • Murfy
    Murfy Member Posts: 342
    edited September 2018

    CPB, what was your tumor size, cancer grade, and Ki-67 score? This would tell us/you how fast growing it was and might explain your Oncotype score.

  • CPB1167
    CPB1167 Member Posts: 24
    edited September 2018

    I am not familiar with the terminology (what is the ki-67 score?), here is the path report, I realize this is my decision but more explanation of what this report means would be great. Thanks.


    - Tumor #1 is grade 2 (3+2+2) and 2.1 cm in maximum dimension.
    - Tumor #2 is grade 1 (2+2+1) and 1.6 cm in maximum dimension.

    - Ductal carcinoma in situ (DCIS), nuclear grade 2, cribriform type, with necrosis andmicrocalcifications.

    BREAST INVASIVE CARCINOMA CASE SUMMARY

    Lymph node sampling: Sentinel lymph node(s)
    Microscopic
    Tumor size: 2.1cm
    Histologic type: Invasive carcinoma of no special type (ductal, not otherwise specified)
    Histologic grade (Nottingham): Grade 2 (scores of 6 or 7)
    Tubule formation: Score 3
    Nuclear pleomorphism: Score 2
    Mitotic rate: Score 2
    Prognostic markers: Performed on accession/block #: GHS-18-4374 part A
    Estrogen receptor: Positive
    Percent cells staining: 91-100%
    Staining intensity: Strong
    Progesterone receptor: Positive
    Percent cells staining: 81-90%
    Staining intensity: Strong
    HER2 immunohistochemistry: Negative (1+)


    Radiographic correlation: Preoperative imaging report(s) were reviewed.
    Tumor focality: Multiple biologically separate invasive carcinomas
    Features of separate invasive carcinoma(s)
    See Additional Findings section below
    Ductal carcinoma in situ: Present
    Negative for extensive intraductal component
    Comment(s): Predominantly associated with tumor #2 (butterfly clip)
    Treatment effect: No known presurgical therapy
    Lymph-vascular invasion: Present
    Microcalcifications: Present in DCIS
    Margins: Uninvolved by invasive carcinoma:
    Distance from closest margin: >1 cm
    Closest: Posterior margin and: Uninvolved by DCIS

    Distance from closest margin: >1 cm
    Closest: Posterior margin
    Regional lymph nodes
    Number with macrometastasis: 0
    Number with micrometastases: 0
    Number with isolated tumor cells only: 0

    Total number of lymph nodes examined: 4
    Number of sentinel nodes examined: 4
    Pathologic staging (pTNM)
    TNM descriptors: m (multiple primary tumors)
    Primary tumor (pT): pT2
    Regional lymph nodes (pN): pN0
    pN modifier: (sn)

    Additional findings
    Features of separate invasive carcinoma(s):
    Tumor #2: Invasive ductal carcinoma, grade 1, 1.6 cm (measured microscopically from slide E16; 1.4 cm on US).
    ER positive (>91%; strong intensity), PR positive (>91%; strong intensity) and HER2 negative (score 1+)
    Optimal block for special studies: Tumor #1 (E11) and tumor #2 (E16)





  • voraciousreader
    voraciousreader Member Posts: 7,496
    edited September 2018

    based on the most recent TAILORx study, you are a candidate for chemo.


    https://www.cancer.gov/news-events/press-releases/2018/tailorx-breast-cancer-chemotherapy


    Until recently, patients like yourself with “intermediate” OncotypeDX scores, clinicians were not sure if the benefits of chemo outweighed the risks. A few months ago, the long awaited TAILORx study results were released. Now, clinicians feel more comfortable recommending chemo for patients with your score.


    That said, it is your decision. You might ask for a second opinion if you are still unsure. Good luck



  • bluepearl
    bluepearl Member Posts: 961
    edited September 2018

    With a score of 27 AND lymph vascular invasion AND a 7 point difference in recurrence rates I would have been comfortable taking the chemo. That said, it is always what YOU are comfortable with. Wishing you all the best in whatever decision you make!!!!

  • Murfy
    Murfy Member Posts: 342
    edited September 2018

    CPB: the Ki-67 is a marker for cell proliferation. Instead, your pathologist counted mitotic cells and obtained a mitotic rate. Yours was in the intermediate range. Your report suggests that you would be a good candidate for chemo. But if conflicted, do get a second opinion.

    I had to hear three doctor recommendations before I was ready to move forward!

  • lactcondoula
    lactcondoula Member Posts: 4
    edited September 2018

    Does the Oncotype DX accurately predict the increased benefit of having chemo when one has a higher score? I read an article in Annals of Oncology, "Prediction of benefit from chemotherapy in ER-positive/Her2-negative breast cancer--a problem still to be solved" that would suggest that the inclusion of some Her2+ women in the NSABP-B20 and SWOG-8814 trials could affect the stated level of cheotherapy benefit. The authors state "We conclude that neither the RS nor any other currently used gene expression test has demonstrated its ability to predict a benefit from chemotherapy treatment in patients with ER-positive/HER2-negative tumors. Nevertheless, validated gene expression tests providing information incremental to established risk factors continue to be a valuable tool to identify patients with low risk of recurrence having low absolute benefit from chemotherapy."

    My initial diagnosis on June 19 by needle biopsy as follow up for my suspicious mammo was IDC, Stage 1, grade 1. I had a partial mastectomy on July 12. My tumor was classified as pT1c N(sn)0. Although the margins were negative, focal DCIS grade II (Intermediate) was also found with no "xtensive intraductal component. Interesting that intermediate grade for DCIS is defined as "neither well-differentiated nor poorly differentiated," I had a close margin of <1 mm for the DCIS, and I elected to have a re-excision on August 16 to get a larger margin. Both surgeries were a piece of cake for me. i finally got the OncotypeDX score back on August 28. Result was 31, which puts me at the bottom of the high risk group.

    I am 70, in very good health and and do not take prescription meds except an infrequent Ambien. I exercise very regularly (cardio and weight-bearing), limit alcohol to <3-4 drinks/week, have a good diet, and a good weight with BMI of 24. There is no history of breast cancer in maternal family (unknown paternal hx). I nursed 5 babies for a total time of almost 12 years, and had prior mammograms which said that I had a 4.5% lifetime risk of BC. Go figure.

    Both MOs I have consulted with are recommending 4 cycles of T-C (Taxotere and cyclophosphamide.) One MO likes Tamoxifen and the other, an Aromatase Inhibitor with Zometa for my low bone density along with the chemo. I have deferred starting any treatment until after i return from a long awaited and already once-postponed trip to South America.

    I am hoping that someone with a similar profile/experience will offer me their thoughts/outcomes/concerns about chemo and anti-estrogen therapy. I have not made up my mind which path I will take. Thank you for reading.


  • Meow13
    Meow13 Member Posts: 4,859
    edited September 2018

    lactcon..., what is your pr percentage? I am including a link for you.

    https://www.breastcancer.org/symptoms/diagnosis/in...



  • voraciousreader
    voraciousreader Member Posts: 7,496
    edited September 2018

    lact...the study you refer to is from 2014. Subsequently, the long awaited TAILORx study was presented this year. The results should be part of your discussion with your team. TAILORx was important because it tried to measure whether those patients with “intermediate Oncotype DX scores would benefit from chemo.


    Here are the results:


    https://www.oncotypeiq.com/en-US/announcements/TAILORx?gclid=EAIaIQobChMItv_zy4C03QIVxVmGCh1ZXwIiEAAYASAAEgLItPD_BwE


    With the TAILORx study, we can now say that for certain cohorts of patients, the benefits of chemo outweigh the risks. Based on your score, you would see some benefit.


    That said, you mention that you are relatively healthy. So are many of us. I was 53 when diagnosed. I exercised, ate well, have a BMI of 24, and like you, STILL got breast cancer. I wish I could say that lifestyle will keep a recurrence at bay. But, sadly, it didn't prevent you or me from getting it and I sincerely doubt it will keep us from recurring.


    At 70, you are still young...and healthy. I hope you will read the TAILORx study and have a fruitful discussion with your team....good luck



  • lactcondoula
    lactcondoula Member Posts: 4
    edited September 2018

    I think I read somewhere my ER status was 100% positive. PR status is negative.

  • Meow13
    Meow13 Member Posts: 4,859
    edited September 2018

    You may want to do AI drugs if you are post menopausal, anastrozole works well for er+ and pr-.

  • lactcondoula
    lactcondoula Member Posts: 4
    edited September 2018

    Thank you Meow13. I am leaning toward doing just the endocrine therapy, even though both Tam and the AIs have SE's that are not to be underestimated. Perhaps I need a 3rd opinion to be the tie-breaker...

    Voraciousreader. I had heard about the TailorX study and appreciated the link you provided. Thank you. A quote from the NCI press release about it:

    "The findings suggest that chemotherapy may be considered for the remaining 30 percent of women with HR-positive, HER2-negative, node-negative breast cancer as in 'any age with a recurrence score of 26–100 (17 percent)"

    Interesting that it says "may." I wish the ages of the trial participants who made up this % were part of the report.

    Another point to consider for me. Wouldn't younger women have more of a chance of returning to a similar functional status that they had before chemo than older women? This is what worries me most about chemo. Yes I might live longer with chemo, but at what cost to being able to fully appreciate life in the here and now, and continue to do all things I do now for as long as I can?

    Still considering options, but luckily I have another month and a half before I have to come to a decision. Thank you for reading.

  • lactcondoula
    lactcondoula Member Posts: 4
    edited September 2018

    Thank you Meow13. I am leaning toward doing just the endocrine therapy, even though both Tam and the AIs have SE's that are not to be underestimated. Perhaps I need a 3rd opinion to be the tie-breaker...

    Voraciousreader. I had heard about the TailorX study and appreciated the link you provided. Thank you. A quote from the NCI press release about it:

    "The findings suggest that chemotherapy may be considered for the remaining 30 percent of women with HR-positive, HER2-negative, node-negative breast cancer as in 'any age with a recurrence score of 26–100 (17 percent)"

    Interesting that it says "may." I wish the ages of the trial participants who made up this % were part of the report.

    Another point to consider for me. Wouldn't younger women have more of a chance of returning to a similar functional status that they had before chemo than older women? This is what worries me most about chemo. Yes I might live longer with chemo, but at what cost to being able to fully appreciate life in the here and now, and continue to do all things I do now for as long as I can?

    Still considering options, but luckily I have another month and a half before I have to come to a decision. Thank you for reading.

  • voraciousreader
    voraciousreader Member Posts: 7,496
    edited September 2018

    lact....regarding age....TailorX also mentions age...for those patients younger than 50, with scores beginning at 16, they should consider chemo. So....patients of any age with scores beginning at 25 should benefit AND patients less than age 50, with scores beginning at 16 should benefit.


    Another study that might be interesting to premenopausal women would be the SOFT and TEXT trials....


    http://www.ascopost.com/issues/july-25-2018/8-year-update-of-soft-and-text-trials/

  • Murfy
    Murfy Member Posts: 342
    edited September 2018

    Lactcondoula: I'm guessing the Grade 1 IDC was Oncotyped and found to be a 31?! Both MOs are probably recommending TCX4 because of your Oncotype score and your overall good health.

    Here is an interesting article about treatment options and explanations for 70 yo ladies with your type of BC.


    https://www.cancernetwork.com/adjuvant-therapy-bre...

  • Meow13
    Meow13 Member Posts: 4,859
    edited September 2018

    Lactcondoula, the score is probably that high from pr 0% coupled with highly er positive.

    Here is an article there is another one dated 2014 basically saying same thing, Tamoxifen doesn't work as well.

    http://www.cancernetwork.com/articles/anastrozole-...

    Something to consider when you are low grade, the combination er+ pr- has been associated with more aggressive behavior. AI drugs seem to be very effective in our case.

    Lmurphy, I suspect your tumor falls into the more aggressive category.


  • Murfy
    Murfy Member Posts: 342
    edited September 2018

    Ahh, I missed the PR-. That would explain the RS 31.

  • Meow13
    Meow13 Member Posts: 4,859
    edited September 2018

    I don't include my stat summary because of the public nature of BCO and the tracking with outbrain. It is kind of a pain to write each time in my post but I feel more comfortable doing that.

Categories